KINESCIENCES
- Biotech or pharma, therapeutic R&D
KINE-101 has completed a Phase 1 study in the US demonstrating a good safety & tolerability profile.
KINE-101 is currently undergoing a Phase 1b/2a clinical study in CIDP patients.
KINE-501 is preclinical proof-of-concept demonstrated in AD animal model.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}